Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 2Lymphoma, B-Cell 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Erectile Dysfunction 1Carcinoma, Hepatocellular 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 64Androgen Antagonists 59Abiraterone Acetate 58apalutamide 56Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Cell- and Tissue-Based Therapy × 1 year × Clear all
NCT01089387 2025-12-04

INSTIN

Institut National de la Santé Et de la Recherche Médicale, France

Phase 1/2 Completed
18 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡